Skip to content
naulon
Not checkedNot checked for notices yet.

Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers

Pugnière Martine, Ychou Marc, Foulquier Elodie and 5 more

BMC Cancer · 2004

doi:10.1186/1471-2407-4-75 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Human monoclonal antibodies (MAbs) are needed for colon cancer radioimmunotherapy (RIT) to allow for repeated injections. Carcinoembryonic antigen (CEA) being the reference antigen for immunotargeting of these tumors, we developed human anti-CEA MAbs.</p> <p>Methods</p> <p>XenoMouse<sup>®</sup>-G2 animals were immunized with CEA. Among all the antibodies produced, two of them, VG-IgG2κ and VG-IgM, were selected for characterization <it>in vitro </it>in comparison with the human-mouse chimeric anti-CEA MAb X4 using flow cytometry, surface plasmon resonance, and binding to radiolabeled soluble CEA and <it>in vivo </it>in human colon carcinoma LS174T bearing nude mice.</p> <p>Results</p> <p>Flow cytometry analysis demonstrated binding of MAbs on CEA-expressing cells without any binding on NCA-expressing human granulocytes. In a competitive binding assay using five reference MAbs, directed against the five Gold CEA epitopes, VG-IgG2κ and VG-IgM were shown to be directed against the Gold 4 epitope. The affinities of purified VG-IgG2κ and VG-IgM were determined to be 0.19 ± 0.06 × 10<sup>8 </sup>M<sup>-1 </sup>and 1.30 ± 0.06 × 10<sup>8 </sup>M<sup>-1</sup>, respectively, as compared with 0.61 ± 0.05 × 10<sup>8 </sup>M<sup>-1 </sup>for the reference MAb X4. In a soluble phase assay, the binding capacities of VG-IgG2κ and VG-IgM to soluble CEA were clearly lower than that of the control chimeric MAb X4. A human MAb concentration of about 10<sup>-7 </sup>M was needed to precipitate approximatively 1 ng <sup>125</sup>I-rhCEA as compared with 10<sup>-9 </sup>M for MAb X4, suggesting a preferential binding of the human MAbs to solid phase CEA. <it>In vivo</it>, 24 h post-injection, <sup>125</sup>I-VG-IgG2κ demonstrated a high tumor uptake (25.4 ± 7.3%ID/g), close to that of <sup>131</sup>I-X4 (21.7 ± 7.2%ID/g). At 72 h post-injection, <sup>125</sup>I-VG-IgG2κ was still concentrated in the tumor (28.4 ± 11.0%ID/g) whereas the tumor concentration of <sup>131</sup>I-X4 was significantly reduced (12.5 ± 4.8%ID/g). At no time after injection was there any accumulation of the radiolabeled MAbs in normal tissues. A pertinent analysis of VG-IgM biodistribution was not possible in this mouse model in which IgM displays a very short half-life due to poly-Ig receptor expression in the liver.</p> <p>Conclusion</p> <p>Our human anti-CEA IgG2κ is a promising candidate for radioimmunotherapy in intact form, as F(ab')<sub>2 </sub>fragments, or as a bispecific antibody.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.